Treatment Set TS329109 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Alternaria Alternata; Poa Pratensis Pollen; Lolium Perenne Pollen; Phleum Pratense Pollen; Ulmus Americana Pollen; Acer Negundo Pollen; Quercus Alba Pollen; Ambrosia Artemisiifolia Pollen.
| Product ID | 49288-0733_b29faef0-2249-45b7-974b-212faa8c91d8 |
| NDC | 49288-0733 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Treatment Set TS329109 |
| Generic Name | Treatment Set Ts329109 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ALTERNARIA ALTERNATA; POA PRATENSIS POLLEN; LOLIUM PERENNE POLLEN; PHLEUM PRATENSE POLLEN; ULMUS AMERICANA POLLEN; ACER NEGUNDO POLLEN; QUERCUS ALBA POLLEN; AMBROSIA ARTEMISIIFOLIA POLLEN |
| Active Ingredient Strength | 0 g/mL; [BAU]/mL; [BAU]/mL; [BAU]/mL; g/mL; g/mL; g/mL; [AU]/mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Non-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS],Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-10-21 |
| Ingredient | Strength |
|---|---|
| ALTERNARIA ALTERNATA | .01 g/mL |
| SPL SET ID: | 4774e45e-d34c-4520-bf4c-6f46e98a0a8c |
| Manufacturer | |
| UNII |
|
| Pharm Class PE | |
| PHarm Class EPC | |
| NUI Code |